HEAT ALERT

Heat advisory issued for Bronx through 9 p.m. Wednesday.

Possible 4th COVID-19 vaccine Novavax heading to FDA approval

A new vaccine could soon be on the market as Food and Drug Administration advisers are now backing a new shot from Novavax.

News 12 Staff

Jun 8, 2022, 9:47 AM

Updated 769 days ago

Share:

A new vaccine could soon be on the market as Food and Drug Administration advisers are now backing a new shot from Novavax. In addition, kids under 5 may soon be able to be legible to get their COVID-19 vaccine.
If approved, Novavax would be the fourth vaccine option available to the public. Although it has already been backed by advisers the vaccine is now awaiting FDA approval.
This comes after the company reported its shot's efficacy is over 90% against mild, moderate or severe infection.
If the vaccines are approved by the FDA, it will head to the Centers for Disease Control and Prevention for approval. Novavax is already available in Canada and parts of Europe.
An FDA official says another vaccine choice could entice people, who may have been hesitant to get the shot to roll up their sleeves.
This all comes as the youngest age group — children under 5 years old — could soon be approved to get vaccinated.
The FDA is also meeting next week to discuss approval for Pfizer and Moderna shots for children under 5 years old.


More from News 12